Alivus Life Sciences Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Alivus Life Sciences Ltd filed with BSE on 07 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Alivus Life Sciences reported Q1 FY'27 revenue of INR640 crores, up 6.4% year-on-year, with non-GPL business growing 26.5% while GPL business declined 52.6% due to inventory rationalization. Gross margin improved to 60.2% and EBITDA margin rose to 36.6%, aided by product mix, operational efficiency and forex gains. Management guided to full-year revenue growth of 10% to 12% and EBITDA margins in the 30% to 32% range, with growth skewed toward the second half of the year.
Numbers mentioned
Revenue: INR640 crores (Q1 FY'27)
p. 3
“We reported revenues of INR640 crores, which is a 6.4% year-on-year growth during the quarter.”
Yasir Rawjee, page 3 of the filed PDF · View the filing
Non-GPL business growth: 26.5% (Q1 FY'27 YoY)
p. 3
“Our non-GPL business delivered strong growth of 26.5% year-on-year, driven by successful new product launches and strong demand across all geographies.”
Yasir Rawjee, page 3 of the filed PDF · View the filing
GPL business decline: 52.6% (Q1 FY'27 YoY)
p. 4
“a decline of 52.6% year-on-year”
Yasir Rawjee, page 4 of the filed PDF · View the filing
Gross margin: 60.2% (Q1 FY'27)
p. 4
“a favourable product mix and newer launches helped improve gross margins to 60.2%, an increase in 510 basis points year-on-year”
Yasir Rawjee, page 4 of the filed PDF · View the filing
EBITDA margin: 36.6% (Q1 FY'27)
p. 4
“650 basis points Y-o-Y improvement in EBITDA margins to 36.6%”
Yasir Rawjee, page 4 of the filed PDF · View the filing
CDMO business growth: 3.8% (Q1 FY'27 YoY)
p. 4
“Our CDMO business recorded 3.8% Y-o-Y growth during the first quarter.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
DMF and CEP filings: 617 (as on June 30, 2026)
p. 4
“The pipeline remains robust, with 617 DMF and CEP filings globally as on June 30.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
High-potent API products in active grid: 29
p. 4
“Our high-potent API portfolio continues to advance with 29 products in the active grid, representing a total addressable market of $82 billion.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
Gross profit: INR385 crores (Q1 FY'27)
p. 5
“Gross profit for the quarter was INR385 crores, up 16.3% year-on-year.”
Tushar Mistry, page 5 of the filed PDF · View the filing
EBITDA: INR234 crores (Q1 FY'27)
p. 5
“EBITDA for the quarter was at INR234 crores, up 29.1% year-on-year.”
Tushar Mistry, page 5 of the filed PDF · View the filing
PAT: INR160 crores (Q1 FY'27)
p. 5
“PAT for the quarter stood at INR160 crores with PAT margins at 25%.”
Tushar Mistry, page 5 of the filed PDF · View the filing
CVS and CNS contribution to top line: 58% (Q1 FY'27)
p. 5
“CVS and CNS continued to anchor growth during the quarter, together contributing 58% to the top line.”
Tushar Mistry, page 5 of the filed PDF · View the filing
Chronic therapies share of top line: 74% (Q1 FY'27)
p. 5
“Overall, chronic therapies accounted for 74% of top line in Q1 FY '27.”
Tushar Mistry, page 5 of the filed PDF · View the filing
R&D expenditure: INR24 crores, 3.7% of sales (Q1 FY'27)
p. 5
“R&D expenditure for Q1 FY '27 was INR24 crores, which was 3.7% of our sales.”
Tushar Mistry, page 5 of the filed PDF · View the filing
Capex: INR85 crores (Q1 FY'27)
p. 5
“our capex for the quarter stood at INR85 crores”
Tushar Mistry, page 5 of the filed PDF · View the filing
Free cash flow: INR90 crores (Q1 FY'27)
p. 5
“We generated a strong free cash flow of INR90 crores, leading to cash and cash equivalents including short-term investments of INR880 crores as of 30th June 2026.”
Tushar Mistry, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 10% to 12% · FY '27
stated firmly by Yasir Rawjee
p. 4
“We are guiding for revenue growth of 10% to 12% in FY '27 with growth skewed towards H2 FY '27.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
EBITDA margin — 30% to 32% · FY '27
stated firmly by Yasir Rawjee
p. 4
“We also remain confident of sustaining EBITDA margins in the 30% to 32% range.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
EBITDA margin upside — up to 34%
stated conditionally by Yasir Rawjee
p. 6
“We can guide to a better margin, frankly. I mean, even up to 34%. The issue is this war situation, and what it's doing to raw material prices.”
Yasir Rawjee, page 6 of the filed PDF · View the filing
GPL business growth — flattish · FY '27
stated conditionally by Yasir Rawjee
p. 4
“While growth in the GPL business is expected to remain flattish in FY '27, the business has been historically weighted towards the second half of the year and we expect a similar trend to play out this year, resulting in a stronger H2 performance.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
Capex — approximately INR540 crores · FY '27
stated firmly by Tushar Mistry
p. 5
“We expect to incur a capex of approximately INR540 crores in FY '27.”
Tushar Mistry, page 5 of the filed PDF · View the filing
Solapur facility commissioning — operational · early Q3 FY '27
stated firmly by Yasir Rawjee
p. 4
“There's a little bit of a delay, but it's going to be operational in early Q3 of FY '27.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
CDMO business momentum — second half of the year
stated conditionally by Yasir Rawjee
p. 4
“However, we can expect the segment to gain momentum in the second half of the year, supported by contributions from newly added projects.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
R&D expenditure as % of sales — around 4%
stated as an aspiration by Yasir Rawjee
p. 11
“So we should sort of end up at a steady state of around 4%.”
Yasir Rawjee, page 11 of the filed PDF · View the filing
CDMO contracts — 2 new CDMO contracts · early H2 FY '27
stated firmly by Yasir Rawjee
p. 7
“It's on track.”
Yasir Rawjee, page 7 of the filed PDF · View the filing
Solapur regulatory inspection — within a year of Solapur becoming operational
stated as an aspiration by Yasir Rawjee
p. 8
“Solapur will be up and running by Diwali and we are going to trigger an inspection within a year from some major regulatory agencies, so we've lined up those products.”
Yasir Rawjee, page 8 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed margin gains to launches and operational efficiency, and expects both to continue.
Answered by Yasir Rawjee
Asked by Ahmed: Are the improved gross margins sustainable or will they normalize as new launches mature?
p. 5
“So the 2 main reasons are launches and operational efficiency. The margins from launches will not just drop off.”
Yasir Rawjee, page 5 of the filed PDF · View the filing
Management said they could guide higher but are being cautious due to the war situation affecting raw material prices.
Answered by Yasir Rawjee
Asked by Ahmed: Why is the EBITDA margin guidance conservative given sustainable gross margins?
p. 6
“Yes. We can guide to a better margin, frankly. I mean, even up to 34%. The issue is this war situation, and what it's doing to raw material prices.”
Yasir Rawjee, page 6 of the filed PDF · View the filing
Management said the GPL customer is a large, longstanding one with over 50 commercial products supplied, so Q1 is not representative of the full year.
Answered by Yasir Rawjee
Asked by Ahmed: What gives confidence that GPL will be flattish for the full year despite the Q1 decline?
p. 6
“That's exactly right. They are an old customer and a very big customer spread out. There are more than 50 commercial products that we supply them.”
Yasir Rawjee, page 6 of the filed PDF · View the filing
CFO said the 32% guidance factors this in, with upside to around 34% possible, but margins could come down to around 34% in a steady state as GPL returns.
Answered by Tushar Mistry
Asked by Koustav: Will EBITDA margins blend lower as GPL revenue recovers in H2 given non-GPL is more margin accretive?
p. 8
“And that's the reason why we are giving 32% margin guidance and Doctor mentioned, that it can go to 34%. But given the current quarter is 36.6%, if GPL comes in, it can come down to around 34% in a steady-state scenario.”
Tushar Mistry, page 8 of the filed PDF · View the filing
Management said they are deliberately calibrated in bringing on new capacity to avoid under-absorption, prioritizing getting Solapur Phase 1 and 1.1 operational and audited first.
Answered by Yasir Rawjee
Asked by Pratik Kothari: Why has Solapur Phase 3 been delayed and how is capacity build-out being approached?
p. 10
“So we don't want to hurry it up. And our experience on brownfield is that we are able to put -- because then it's only the manufacturing infrastructure, and that can come up in about 8, 9 months' time.”
Yasir Rawjee, page 10 of the filed PDF · View the filing
Management said Solapur will be loaded with large-volume intermediates for captive consumption and will handle ROW business initially while Dahej and Ankleshwar expansions support reg market growth.
Answered by Yasir Rawjee
Asked by Ahmed: Given high utilization, is capacity enough to support double-digit growth in FY'27 and FY'28 before Solapur is inspected?
p. 11
“The thing is Solapur is not going to run empty. In Phase 1 and 1.1, we've already mapped out enough products to come out of Solapur.”
Yasir Rawjee, page 11 of the filed PDF · View the filing
Management said they are in active discussions on about 7 new projects, with current revenue coming from 5 existing projects.
Answered by Yasir Rawjee
Asked by Bhawana Israni: How many new CDMO customers or projects has Alivus added recently and how is the pipeline developing?
p. 13
“One second, I talked about 7 new inquiries that we are working on. The current revenue is coming out of 5 projects, okay?”
Yasir Rawjee, page 13 of the filed PDF · View the filing
Risks flagged
War situation impacting raw material prices
p. 6
“The issue is this war situation, and what it's doing to raw material prices. So we need to be a little bit cautious.”
Yasir Rawjee, page 6 of the filed PDF · View the filing
Raw material price increases, starting with solvents and now KSM
p. 9
“While we are seeing the raw material prices are going up. And in fact, it started from solvents and then now to KSM.”
Tushar Mistry, page 9 of the filed PDF · View the filing
Inventory rationalization causing steep GPL decline
p. 4
“GPL has been muted as a result of inventory rationalization.”
Yasir Rawjee, page 4 of the filed PDF · View the filing
Slowdown with labor affecting Solapur timeline
p. 10
“Part of it was also -- there's been a slowdown with labor and a few other things.”
Yasir Rawjee, page 10 of the filed PDF · View the filing
Inventory build-up expected to increase
p. 9
“There will be a slight increase on the inventory side is what we are seeing as we keep on building inventory so that we are able to continue to support our customers in a timely manner and at more predictable prices.”
Tushar Mistry, page 9 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.